Newlimit, a longevity biotech company co-founded by Coinbase CEO Brian Armstrong, has raised $435 million in a Series C funding round led by Founders Fund. The round roughly tripled the startup's valuation to about $3.1 billion, underscoring how wealth generated in crypto is increasingly bankrolling frontier science.
Founders Fund leads the charge
The Series C was led by Founders Fund, the venture firm known for backing bold, long-shot bets. Newlimit didn't disclose whether existing investors participated or the exact equity stake, but the round size — large even by biotech standards — signals conviction that longevity research can deliver both scientific and financial returns. Brian Armstrong co-founded the company in 2021, and his crypto fortune from Coinbase helped seed the project. This round pushes Newlimit into the upper tier of well-funded longevity startups.
Crypto cash meets long odds
The funding round is the latest example of crypto wealth migrating into longevity science. A handful of high-net-worth crypto founders have backed anti-aging ventures, betting that extending human healthspan is the next big market. For Armstrong, the investment is personal: he has said he wants to live longer and sees biotech as the next frontier after crypto. The $435 million haul suggests investors agree, even as the broader crypto market remains volatile.
What Newlimit will do with the money
Newlimit focuses on cellular reprogramming and epigenetic reset — approaches that aim to reverse hallmarks of aging. The company has not published human trial data yet, but the Series C cash is expected to fund preclinical work and early-stage clinical studies. With $3.1 billion valuation, Newlimit now has the runway to hire top researchers and expand lab capacity. Whether that translates into therapies remains an open question — longevity biotech is littered with failures — but Armstrong and Founders Fund are betting on a long timeline.
Newlimit hasn't announced a timeline for its first clinical trial. The company is expected to use the Series C to push at least one candidate into human testing within the next 18 months. For now, the market is watching whether the flow of crypto fortunes into biotech accelerates — or hits the same regulatory and scientific roadblocks that have tripped up other well-funded longevity startups.
